Mounjaro strength: the six doses and how titration works

What are the six Mounjaro strengths, and what does each pen actually contain?

Each Mounjaro KwikPen is a pre-filled, multi-dose device containing tirzepatide solution for four weekly subcutaneous injections. You can find a detailed breakdown of what each of the six Mounjaro strengths contains and how they differ, covering 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg per dose. The pen itself doesn't look different from one strength to the next in terms of size, but the concentration inside changes, so strengths are not interchangeable and should never be substituted without a prescriber's instruction.

The full range of tirzepatide strengths is set by Eli Lilly's licensed Summary of Product Characteristics (SmPC). Every strength is subject to the same prescription-only requirement and the same MHRA Black Triangle monitoring status, which means any new safety signals are actively tracked and reported. The NHS medicines page for tirzepatide, available on NHS.co.uk, provides a plain-language summary of how the medicine is used and what to watch for at any dose.

It's worth being clear about one practical point: a pen at one strength cannot simply be used as a "half dose" of the next one up. The device is pre-set. If your prescriber moves you to 7.5 mg, you need the 7.5 mg pen, not two injections from a 5 mg pen spread across the week.

Why does treatment start at 2.5 mg even if the target dose is 15 mg?

This is probably the question our prescribers are asked most often at the point of starting treatment. The 2.5 mg dose was designed specifically to ease your gastrointestinal system into the medicine. Nausea, loose stools and indigestion are common in the first weeks; starting low reduces how pronounced those effects are. The 2.5 mg dose is not expected to drive meaningful weight loss on its own, its job is adjustment, not treatment.

From there, the titration ladder climbs in 2.5 mg steps, with a minimum of four weeks at each level before moving up. Which Mounjaro strength you'll actually need depends on how your body responds at each stage and whether side effects settle. Some people find a mid-range dose, such as 7.5 mg or 10 mg, works well for them and their prescriber decides there's no clinical reason to push higher. Others titrate to 12.5 mg or 15 mg over several months.

The prescriber's job at each review is to weigh tolerability against progress. That's why every repeat at nume is clinically re-reviewed before dispatch, not rubber-stamped.

Does a higher Mounjaro strength always mean better results?

In the SURMOUNT-1 trial, higher doses were associated with greater average weight loss: participants on 15 mg saw around 20–21% average body-weight reduction over 72 weeks. The 10 mg and 12.5 mg arms showed meaningful but somewhat lower average losses. That dose-response relationship is real, but it doesn't translate into a simple rule that everyone should push to 15 mg as quickly as possible.

Tolerability matters. Side effects (predominantly nausea, vomiting and changes in bowel habit) tend to be most noticeable after starting or after a dose increase, and they do ease for most people within days to a couple of weeks. But for some, stepping up too quickly makes treatment unsustainable. A dose you can stay on consistently is more useful than a higher one you stop after six weeks.

If you're comparing Mounjaro to Wegovy (semaglutide 2.4 mg), the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, reported greater average weight loss with tirzepatide, context worth reading if you're still deciding between the two. There's a broader look at which Mounjaro strength tends to be used for weight loss if that comparison is useful.

What if I need to stay on a lower strength for longer, is that a problem?

Not at all. The titration schedule sets a minimum time at each dose, not a maximum. If you experience persistent side effects at 5 mg, for instance, your prescriber may recommend holding at that level for an additional four weeks before stepping up. That's standard clinical practice, not a setback.

Staying at a lower dose long-term is also a legitimate clinical outcome. The goal is sustained, safe weight management, not hitting the highest number on the label. Some people plateau at a mid-range strength and their prescriber reviews whether there is benefit in continuing to titrate or whether the current dose is the right maintenance level.

Questions about cost across different doses are reasonable too. There is a straightforward breakdown of what Mounjaro costs in the UK if you want to understand how pricing varies by strength. And if you're ready to talk through which dose would be the right starting point for your situation, starting a free consultation is the practical next step, a GPhC-registered prescriber reads every response the same day it's submitted.